Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines

Torricelli Piera; Antonelli Francesco; Ferorelli Pasquale; De Martino Angelo; Shevchenko Anna; Beninati Simone

doi:doi:10.11648/j.crj.20140202.13

| Peer-Reviewed

Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines

Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, Beninati Simone

Published in Cancer Research Journal (Volume 2, Issue 2)

Received: 10 February 2014 Published: 30 March 2014

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy

Published in	Cancer Research Journal (Volume 2, Issue 2)
DOI	10.11648/j.crj.20140202.13
Page(s)	29-32
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2014. Published by Science Publishing Group

Keywords

Food Supplements, (ER)+/(ER)- Breast Cancers, Cancer Cell Survival

References

[1]	Carter B. S., Beaty T. H., Steinberg G. D., Childs B. & Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 3367–3371.
[2]	Muraca L, Leung D, Clark A, Beduz MA, Goodwin P. Breast cancer survivors: taking charge of lifestyle choices after treatment. Eur J Oncol Nurs. 2011;15(3):250-253.
[3]	Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents.Asian Pac J Cancer Prev. 2012;13(2):427-436.
[4]	Arcangeli S., Pinzi V., Arcangeli G. Epidemiology of prostate cancer and treatment remarks. World J. Radiol. 2012;4:241–246.
[5]	Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy.Nat Rev Drug Discov. 2013;12(12):931-947.
[6]	Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA, Quiles JL.Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies.Crit Rev Oncol Hematol. 2011;80(3):347-368.
[7]	Antonelli F & Beninati S. Enhanced survival of B16-F10 melanoma tumour-bearing C57BL6/N mice treated with a mixture of antioxidants in: Recent Res Devel in Life Sci. 2011;5:51-60 Research Signpost, Trivandrum India
[8]	Keawpradub N, Amooquaye E.E, Burke PJ, Houghton PJ. Cytotoxic activity of indole alkaloids from Alstonia macrophylla. Planta Medica 1999;65: 311–315.
[9]	Skehan P, Storeng R, Scudiero D, Monks A, McMahon I, Vistica D, Waren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer drug screening. Journal of National Cancer Institute. 1990: 82:1107–1112.
[10]	Lipsett MB. Prospects in endocrinology for chemotherapy. Cancer Res. 1969;29(12):2408-2411.
[11]	Jensen EV, and Jacobson H. I. Basic Guides to the Mechanism of Estrogen Action. Recent Progr. Hormone Res.1962;18: 387-408.
[12]	Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8(9):1377-1385.
[13]	Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study.Cancer Prev Res (Phila). 2014;7(1):161-168.
[14]	Osborne CK, McGuire WL.Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979;130(5):401-407.

Cite This Article

Plain Text BibTeX RIS

APA Style

Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. (2014). Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Research Journal, 2(2), 29-32. https://doi.org/10.11648/j.crj.20140202.13

Copy | Download

ACS Style

Torricelli Piera; Antonelli Francesco; Ferorelli Pasquale; De Martino Angelo; Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res. J. 2014, 2(2), 29-32. doi: 10.11648/j.crj.20140202.13

Copy | Download

AMA Style

Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res J. 2014;2(2):29-32. doi: 10.11648/j.crj.20140202.13

Copy | Download

@article{10.11648/j.crj.20140202.13,
  author = {Torricelli Piera and Antonelli Francesco and Ferorelli Pasquale and De Martino Angelo and Shevchenko Anna and Beninati Simone},
  title = {Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {2},
  pages = {29-32},
  doi = {10.11648/j.crj.20140202.13},
  url = {https://doi.org/10.11648/j.crj.20140202.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20140202.13},
  abstract = {A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy},
 year = {2014}
}

Copy | Download

TY  - JOUR
T1  - Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines
AU  - Torricelli Piera
AU  - Antonelli Francesco
AU  - Ferorelli Pasquale
AU  - De Martino Angelo
AU  - Shevchenko Anna
AU  - Beninati Simone
Y1  - 2014/03/30
PY  - 2014
N1  - https://doi.org/10.11648/j.crj.20140202.13
DO  - 10.11648/j.crj.20140202.13
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 29
EP  - 32
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20140202.13
AB  - A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy
VL  - 2
IS  - 2
ER  -

Copy | Download

Author Information

Torricelli Piera

Department SPES, University of Molise, Campobasso, Italy
Antonelli Francesco

Department of Biology, University of Tor Vergata, Rome, Italy
Ferorelli Pasquale

Department of Biology, University of Tor Vergata, Rome, Italy
De Martino Angelo

Department of Biology, University of Tor Vergata, Rome, Italy
Shevchenko Anna

People’s Friendship University of Russia, Moscow, Russia
Beninati Simone

Department of Biology, University of Tor Vergata, Rome, Italy

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. (2014). Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Research Journal, 2(2), 29-32. https://doi.org/10.11648/j.crj.20140202.13

Copy | Download

ACS Style

Torricelli Piera; Antonelli Francesco; Ferorelli Pasquale; De Martino Angelo; Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res. J. 2014, 2(2), 29-32. doi: 10.11648/j.crj.20140202.13

Copy | Download

AMA Style

Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res J. 2014;2(2):29-32. doi: 10.11648/j.crj.20140202.13

Copy | Download

@article{10.11648/j.crj.20140202.13,
  author = {Torricelli Piera and Antonelli Francesco and Ferorelli Pasquale and De Martino Angelo and Shevchenko Anna and Beninati Simone},
  title = {Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {2},
  pages = {29-32},
  doi = {10.11648/j.crj.20140202.13},
  url = {https://doi.org/10.11648/j.crj.20140202.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20140202.13},
  abstract = {A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy},
 year = {2014}
}

Copy | Download

TY  - JOUR
T1  - Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines
AU  - Torricelli Piera
AU  - Antonelli Francesco
AU  - Ferorelli Pasquale
AU  - De Martino Angelo
AU  - Shevchenko Anna
AU  - Beninati Simone
Y1  - 2014/03/30
PY  - 2014
N1  - https://doi.org/10.11648/j.crj.20140202.13
DO  - 10.11648/j.crj.20140202.13
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 29
EP  - 32
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20140202.13
AB  - A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy
VL  - 2
IS  - 2
ER  -

Copy | Download